Respironics' CEO Honored by Pittsburgh Technology Council

John Miclot Named CEO of the Year

Murrysville, PA - November 10, 2005

Respironics, Inc. (NASDAQ/NMS Symbol: RESP) announced today that John Miclot, president and CEO of Respironics, was recently named CEO of the Year by the Pittsburgh Technology Council at the Tech 50 Awards. For the past eight years, the Council has recognized the region's fastest growing and most innovative companies and their leaders. Miclot was selected based on criteria that included the performance of Respironics, the extent to which he has contributed to the company's performance, overall leadership qualities and the esteem in which he is held by his peers.

"It's truly an honor to be recognized by the Pittsburgh Technology Council, but I give the credit for this award to all of the people in our company. Respironics has more than 4,100 associates - I'm only one of them," said Miclot. "All of us at Respironics have worked diligently toward exceeding our company goals, and I believe our performance from this past fiscal year proves it."

In his second year at the helm of the Murrysville, PA-based company, Miclot reported that Respironics has met or exceeded financial expectations for 24 consecutive quarters. For the year ending June 30, net sales grew to $911.5 million, a 20 percent increase compared to the reported $759.5 million a year ago. The Company plans to exceed a billion dollars in revenue for fiscal year 2006.  

Respironics is a leading developer, manufacturer and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing valued solutions to help improve outcomes for patients, clinicians and healthcare providers. Respironics markets its products in more than 131 countries and employs more than 4,100 associates worldwide. Further information can be found on the Company's Web site: www.respironics.com.

This document contains forward-looking statements, including statements relating to, among other things, developments in the healthcare industry; the success of the Company's marketing, sales and promotion programs; future sales and acceptance of the Company's products and programs; the timing and success of new product introductions; new product development; anticipated cost savings; FDA and other regulatory requirements and enforcement actions; future results from acquisitions; growth rates in foreign markets; regulations and other factors affecting operations and sales outside the United States (including potential future effects of the change in sovereignty of Hong Kong); the effects of a major earthquake, cyber-attack, or other catastrophic event that results in the destruction or disruption of any of our critical business or information technology systems; foreign currency fluctuations; customer consolidation and concentration; increasing price competition and other competitive factors in the sale of products; interest rate fluctuations; expiration of intellectual property rights; intellectual property and related litigation; other litigation; future levels of earnings and revenues; the number of equity awards granted to employees and changes to the Company's stock price; and third-party reimbursement, all of which are subject to change. Actual results may differ materially from those described in any forward-looking statements. Additional information on potential factors that could affect the Company's financial results are included in the reports filed with the SEC, including the reports on Forms 10-K, 10-Q and 8-K.